Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck KGaA, Domain Explore New Immuno-oncology Agents | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Merck KGaA, Domain Explore New Immuno-oncology Agents

Will work to develop and test new agents targeting key adenosine receptors

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck KGaA, which operates its biopharmaceutical business in the U.S. and Canada as EMD Serono, has entered into a collaboration and licensing agreement with Domain Therapeutics of Strasbourg, France, to explore adenosine inhibition in the development of novel immuno-oncology agents. 
 
Adenosine receptor antagonists are small molecules thought to slow tumor progression and improve the response to combination immunotherapies by inhibiting adenosine, a compound generated by cancer cells that inhibits anti-tumor responses by binding to T cells.
 
The companies will work to develop and test new agents targeting key adenosine receptors. Merck KGaA will support research activities and gain worldwide rights to Domain’s next generation of adenosine receptor inhibitors. 
 
“This new generation of adenosine receptor antagonists are an important addition to our immuno-oncology pipeline,” said Laszlo Radvanyi, Senior Vice President, head of Research in Immuno-Oncology at the biopharma business of Merck KGaA, Darmstadt, Germany. “We plan to explore the promise of adenosine receptor antagonists and develop novel compounds to potentially use in new combination immunotherapies for cancer.”
  
“With its growing portfolio of immuno-oncology agents, Merck KGaA, Darmstadt, Germany, is the ideal partner to develop our adenosine programs,” said Pascal Neuville, chief executive officer, Domain Therapeutics. “As a strong collaborator with a leading investigational checkpoint inhibitor, we are confident that through Merck KGaA, Darmstadt, Germany, our programs will progress rapidly.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics